Search
NS-2359
go.drugbank.com/drugs/DB05805InvestigationalThis mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.
Beraprost
go.drugbank.com/drugs/DB05229InvestigationalBeraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesSYNB1353
go.drugbank.com/drugs/DB17666Investigational[A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. … SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug.
Desmethylprodine
go.drugbank.com/drugs/DB01478ExperimentalIllicitIt is known to be a designer drug, synthesized in 1977, for the purpose of recreational use. Illicit manufacturing has occurred. … Desmethylprodine, a derivative of meperidine, is an opioid analgesic with the potency of morphine.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsFINLAY-FR-1
go.drugbank.com/drugs/DB16524ExperimentalFINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373]. … clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR
Synonyms: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidateZileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnLeukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth musc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsGnRH pharmaccine
go.drugbank.com/drugs/DB05815ExperimentalThe pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation
TG-100801
go.drugbank.com/drugs/DB05075InvestigationalIt is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological
Alunacedase alfa
go.drugbank.com/drugs/DB15736InvestigationalAlunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Categories: Experimental Unapproved Treatments for COVID-19